Skip to main content

Table 3 Synergism between BTK and EGFR inhibitors

From: p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

  Ibrutinib AVL-292 RN486
  Gefitinib Erlotinib Gefitinib Erlotinib Gefitinib Erlotinib
Calu-6 0.04 0.20 0.18 0.18 0.13 0.10
SK-Lu-1 0.02 0.20 0.13 0.17 0.11 0.11
NCI-H1975 0.01 0.01 0.74 0.26 0.34 0.17
NCI-H2228 0.01 ant ant ant 0.18 0.11
  1. Combination Index (CI) was calculated as reported by Fransson (Fransson, A., et al. (2016) J Ovarian Res 9 [1]: 27) and detailed in material and methods
  2. 0.8 < CI < 1.2 = additive effect, CI < 0.8 = synergistic effect (CI < 0.5 = strong synergistic effect), CI > 1.2 = sub-additive effect, ant = antagonistic effect